UK Medical Research Logo Leeds University Logo Liverpool Uni Logo Newcastle Uni Logo Sheffield University Logo UK Medical Research Logo Leeds University Logo Liverpool University Logo Newcastle University Logo Sheffield University Logo
UK Medical Research Logo Leeds University Logo Liverpool Uni Logo Newcastle Uni Logo Sheffield University Logo

Leeds Liverpool Newcastle Sheffield

MRC DiMeN Doctoral Training Partnership

Discovery Medicine North

Current Opportunities

Thank you for your interest in DiMeN DTP PhD studentships, applications for October 2019 entry have now closed. 


In this round, 32 studentships will be fully-funded based on student choice following candidate interviews.  For those of you who have submitted an application, please refer to the "Application overview" and "Eligibility" pages for more information on the selection process.



For information only: Project titles for Oct 2019 entry:

1. From single-molecule to synchrotron:  New tools for investigating the molecular mechanisms of Aicardi-Goutières Syndrome and other aberrant DNA diseases   (Sheffield/  iCASE industry partner: Diamond Light Source Ltd)                                 

2. Developing non-invasive imaging strategies to investigate the effect of kidney disease on cardiovascular health and assess the ameliorative effect of a regenerative medicine therapy    (Liverpool: iCASE industry partner: Nano Biosols)

3. From cells to mind: Relational neurons and computations creating mental structures crucial for learning and memory   (Newcastle/iCASE industry partner: Rogue Resolutions)

4. Optogenetic programming of inflammation - in vivo Opto-GPCR approaches in neutrophils   (Sheffield)

5. Discovering the neuronal signalling mechanism at the heart of cardiac arrhythmias   (Leeds:  iCASE Industry partner: Badrilla Ltd)

6. The in situ 3D molecular structure of Alzheimer’s disease-associated pathology (Leeds)

7. Boosting immunity in chronic lung disease and antimicrobial resistant infection via the IL-33-ST2 axis  (Sheffield: iCASE industry partner: Medimmune)

8. Mass-spectrometry analysis and live cell/zebrafish imaging to discover the function of novel post-translational modifications occurring in hypoxia signalling   (Liverpool)

9. Rationally Designed Reovirus-Based Immunotherapy for Hepatocellular Carcinoma   (Leeds)

10. The role of RNAseH2 in DNA repair and  diseases of aging   (Sheffield) 

11. Understanding asymmetric cell divisions at the onset of life   (Newcastle)

12. Personalised mitochondrial health: a functional and multi-omic assessment to predict individual susceptibility to hepatotoxicity of antiepileptic drugs  (Liverpool)

13. Biochemical and Cryo-EM analysis of cancer-causing pseudokinases   (Liverpool)

14. Ciliogenesis and skeletal muscle regeneration: molecular mechanisms of stem cell maintenance   (Sheffield)

15. Mining the human gut microbiome for novel medically relevant glycoenzymes   (Newcastle)

16. Towards a greater understanding of Atrial Fibrillation: Proteomics and genomics of a common global cardiac rhythm disorder   (Liverpool)

17. Determining how post-transcriptional control of mRNA turnover and translation contributes towards age-associated joint diseases   (Liverpool)

18. Detection of ultra-low frequency heart rate variability markers of disease using AI beat detection and HRV modelling (Liverpool)

19. Development of deubiquitylase (DUB) inhibitors to target interferon-mediated diseases  (Leeds)

20. Developmental imaging of bacterial biofilms with advanced microscopy, image processing and machine learning   (Newcastle)

21. From bench to bedside; using patient-based assays that model the gut microbiome-host interface to aid diagnosis and inform treatment of immune dysregulation   (Newcastle) 

22. Mechanical activation of TGFbeta signaling in arterial disease   (Sheffield)

23. Understanding the molecular pathophysiology of stress on the developing and adult brain   (Sheffield)

24. Building integrated machine learning and genomic approaches to quantitate bone quality and fracture risk   (Sheffield)

25. Ex-vivo normothermic perfusion of organs to minimise ischemia reperfusion injury    (Newcastle)

26. Magnetic resonance imaging of lung fibrosis in interstial lung disease – physics or engineering PhD project   (Sheffield:  Industry partner: Galapagos)

27. The making of a Super Bug.  Understanding the mechanisms of high level antibiotic resistance in Methicillin Resistant Staphylococcus aureus (MRSA)    (Sheffield)

28. Elucidating new redox-signalling mechanisms that help maintain healthy tissues during ageing   (Newcastle/ iCASE industry partner: Nuchido)

29. Gene expression network analysis to identify candidate drivers of treatment resistance in glioblastoma multiforme   (Leeds)

30. Harnessing T cells to target brain metastases   (Leeds)

31. Integrated system for rigorous personalised diagnosis for Giant Cell Arteritis (GCA) with imaging and biopsy tests   (Liverpool)

32. Using bioinformatics to identify pathways regulating pancreatic beta-cell function and survival   (Newcastle/A*STAR: Singapore)

33. Waking up to neurodegenerative diseases: development of an awake mouse preparation to investigate neurovascular dysfunction in ageing and Alzheimer’s disease   (Sheffield)

34. Does an aged egg regain its youth after fertilisation?    (Newcastle) 

35. New treatments for antimicrobial TB via modulation of innate immunity    (Sheffield) 

36. Application of data science to inherited genetic variants of apoptosis genes and susceptibility to breast cancer   (Sheffield)

37. Evolution of antimicrobial resistance in Clostridium difficile   (Sheffield)

38. Genetic epilepsy: identifying mechanisms and potential drug treatments, from nematodes to humans   (Liverpool)

39. Investigating copper storage in Pseudomonas aeruginosa and its role in pathogenicity   (Newcastle)

40. Mechanisms of chronic liver disease associated with hepatitis C virus genotype 3 infection    (Leeds)

41. Role of GPNMB in susceptibility to influenza virus infection: friend or foe?   (Liverpool)

42. The molecular cell biology jigsaw of Parkinson’s disease: bringing the pieces together   (Liverpool)

43. Determination of how killer pathogenic fungi evade human innate immune defences   (Newcastle)

44. Characterising a novel innate immune signalling pathway in tumour-associated macrophages by proteomics    (Newcastle)

45. Functional Characterization of a Truncation Mutation Associated with Intellectual Disability    (Leeds)

46. Interactive effects of affective experiences and ageing processes on brain networks over the life course: a neuroimaging informatics approach   (Newcastle)

47. Mining large international genetic datasets to identify new therapeutic targets in giant cell arteritis through innovative genetic methodology  (Leeds)

48. A personalised model of coronary artery blood flow    (Sheffield)

49. Development of advanced MRI methods for measurement of pulmonary structural and functional change associated with lung disease    (Newcastle)

50. Genomic translocations, super-enhancer hijacking and oncogene activation: from mechanism to therapy   (Newcastle)

51. The direct effect of statins on cardiovascular function   (Liverpool)

52. Defining the link between glucose,  miRNAs and extracellular vesicles in pregnancies complicated by maternal diabetes   (Leeds)

53. Addressing antimicrobial resistance (AMR): Affimers as therapeutic candidates and tools in antibacterial drug discovery   (Leeds. Collaborator/Industry sponsor: Public Health England)  

54. Identifying inhibitors specific to the OPG-kinome: towards novel treatments for Pulmonary Arterial Hypertension (PAH)    (Leeds)

55. Personalised medicine in Joubert syndrome: patient-specific human urine-derived epithelial cells as a disease model and platform for therapeutic development   (Newcastle)

56. Understanding the genetics of melanoma by studying heritable risk factors    (Leeds)

57. Capturing how Hsp90 prevents the formation of cell-disruptive toxic amyloid species by Cryo-EM in a C. elegans model for Alzheimer’s Disease   (Leeds)

58. Use of engineered protein polymers in wound repair   (Newcastle)

59. Proteomics approaches to discover new roles for non-canonical signalling in cancer   (Liverpool) 

60. Development and application of fast Magnetic Resonance Spectroscopic Imaging methods for neuro-chemical profiling   (Leeds)

61. How do neurodegenerative mutations in kinesin-1 alter its structure, motility and cellular function?   (Sheffield)

62. How do superbugs hide from the host? Understanding the mechanisms of innate immune evasion in the opportunistic pathogen Enterococcus faecalis   (Sheffield)

63. Developing novel therapies for babies born with univentricular hearts   (Newcastle)

64. How interferon defends the brain against viral invasion?   (Newcastle)

65. Why do multiple pathogenic viruses including HIV, Influenza, Ebola, Herpesviruses and Adenovirus target the cellular transcription machinery?    (Sheffield) 

66. Mass spectrometry analysis of human tissue to characterise cleavage events resulting in amyloid deposition associated with aortic aneurysm and dissection    (Liverpool)

67. Antiretroviral-induced metabolic toxicity: Role of adipose-miRNAs as mechanistic regulators and toxicity biomarkers   (Liverpool)

68. Breaking up the fight: Defining the spatial requirements for therapeutic modulation of signaling through FcγRIIa   (Leeds)

69. Evaluation of adult stem cell differentiation in the trabecular meshwork of the eye as a regenerative medicine approach for Glaucoma using novel polymer 3D scaffolds   (Liverpool/iCASE industry partner:  SpheriTech Limited)

70. Role of primary cilium in morphogen signalling modulation by Transforming Growth Factor-beta (TGF-beta) and its involvement in tissue fibrosis and aberrant wound healing   (Leeds)

71. Investigating microbiome–host interactions in the preterm gut using metagenomics and stem-cell derived enteroid “mini guts”    (Newcastle)

72. Dissecting INPP5K function: cell biology, structural determination by X-ray crystallography and enzymology of a key protein implicated in muscular dystrophy, insulin signalling, spastic paraplegias and Parkinsonism   (Liverpool)

Any questions regarding DiMeN please contact the DTP manager Emily: